Cornerstone Strengthens Its Scientific Advisory Board

Cornerstone Pharmaceuticals (Cornerstone) has included cancer research scientist, Robert Weinberg, a founding member of the Whitehead Institute for Biomedical Research and a Professor of Biology at MIT, in the company’s Scientific Advisory Board.

Reportedly, Dr. Weinberg has been widely recognised for his discoveries of the first human oncogene (the ras oncogene that causes normal cells to form tumors), and the isolation of the first known tumor suppressor gene – the Rb gene.

Dr. Weinberg said: “I am pleased to join Cornerstone Pharmaceuticals as a member of its Scientific Advisory Board and look forward to helping the company develop vitally important potentially life-sustaining compounds that challenge and hopefully enhance conventional wisdom about treatment for a variety of cancers.”

Robert Shorr, CEO of Cornerstone, said: “We are delighted to welcome Dr. Weinberg to our Scientific Advisory Board. Dr. Weinberg’s accomplishments in cancer research are monumental and we believe his experience, guidance and vision will be of tremendous benefit to the company.”

Cornerstone has also reported that it is currently recruiting patients with solid tumors to advance multiple phase I/II human clinical trials of CPI-613, its lead drug to emerge from the company’s Altered Energy Metabolism Directed (AEMD) technology platform.